Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy

Ads

You May Also Like

FIT Biotech Oy: Liquidity Providing agreement with S-Pankki to expire

FIT Biotech Oy Company release October 3, 2016 at 9:00 am EET                                                                                        Liquidity ...